Sichuan Shuangma: Its holding subsidiary Hubei Jianxiang passes the on-site inspection by the US FDA.

Sichuan Shuangma Announcement: its holding subsidiary Hubei Jianxiang Bio-Pharmaceutical Co., Ltd. underwent an on-site cGMP inspection by the US Food and Drug Administration from March 10th to 14th, 2025. This inspection focused on drug quality assurance, covering core aspects such as quality system, production system, and mainly involved raw materials such as telaprevir, simvastatin, liraglutide, oxytocin, etc. According to the inspection report, Hubei Jianxiang's quality and production systems comply with US FDA standards and passed the on-site inspection. Successfully passing the US FDA on-site inspection for two consecutive times indicates that Hubei Jianxiang's raw material drug production base consistently meets the requirements of the US FDA in terms of quality management systems and production environment facilities, providing assurance for the stable expansion of the company's international business and further enhancing its influence in the international market.